JP2017538669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538669A5 JP2017538669A5 JP2017520986A JP2017520986A JP2017538669A5 JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5 JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017520986 A JP2017520986 A JP 2017520986A JP 2017538669 A5 JP2017538669 A5 JP 2017538669A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- group
- mdsc
- human genetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021102148A JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190370.8A EP3012271A1 (en) | 2014-10-24 | 2014-10-24 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| EP14190370.8 | 2014-10-24 | ||
| PCT/IB2015/058124 WO2016063233A1 (en) | 2014-10-24 | 2015-10-21 | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Division JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538669A JP2017538669A (ja) | 2017-12-28 |
| JP2017538669A5 true JP2017538669A5 (enExample) | 2018-11-29 |
| JP6918279B2 JP6918279B2 (ja) | 2021-08-11 |
Family
ID=51868772
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017520986A Active JP6918279B2 (ja) | 2014-10-24 | 2015-10-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102148A Active JP7253008B2 (ja) | 2014-10-24 | 2021-06-21 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
| JP2023047480A Pending JP2023078398A (ja) | 2014-10-24 | 2023-03-24 | 癌および感染症の治療のために骨髄由来抑制細胞分化を誘導する方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170247464A1 (enExample) |
| EP (4) | EP3012271A1 (enExample) |
| JP (3) | JP6918279B2 (enExample) |
| CA (1) | CA2964203C (enExample) |
| DK (2) | DK3209691T3 (enExample) |
| ES (1) | ES2817074T3 (enExample) |
| HU (1) | HUE050318T2 (enExample) |
| PL (1) | PL3209691T3 (enExample) |
| WO (1) | WO2016063233A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| CN117964732A (zh) | 2015-08-07 | 2024-05-03 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
| PL3341015T5 (pl) | 2015-08-26 | 2024-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Zwiększona deplecja komórek docelowych z blokadą cd47 i immunologicznym agonistą kostymulatorowym |
| EP4186927B1 (en) * | 2015-10-21 | 2025-04-23 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| SMT202400438T1 (it) | 2016-04-14 | 2024-11-15 | Ose Immunotherapeutics | Nuovi anticorpi anti-sirpa e loro applicazioni terapeutiche |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| EP3482772A4 (en) * | 2016-07-05 | 2020-03-04 | National University Corporation Kobe University | ANTI-MEDIUM |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| JP7173971B2 (ja) | 2016-12-09 | 2022-11-16 | アレクトル エルエルシー | 抗ＳＩＲＰ－α抗体及びその使用方法 |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| HRP20230937T1 (hr) | 2017-01-05 | 2023-11-24 | Kahr Medical Ltd. | Pd1-41bbl fuzijski protein i metode korištenja istog |
| PT3565828T (pt) | 2017-01-05 | 2022-02-08 | Kahr Medical Ltd | Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização |
| AU2018210235A1 (en) * | 2017-01-18 | 2019-08-15 | Nant Holdings Ip, Llc | Modulation of tumor cell susceptibility |
| AU2018221745A1 (en) * | 2017-02-15 | 2019-10-03 | The Regents Of The University Of California | Compositions and methods for activating NK cells |
| JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| JP7395471B2 (ja) | 2017-10-13 | 2023-12-11 | オーセ イミュノセラピューティクス | 改変抗ＳＩＲＰａ抗体及びその使用 |
| CN112105646A (zh) | 2018-03-13 | 2020-12-18 | Ose免疫疗法 | 抗人SIRPa v1抗体的用途和生产抗SIRPa v1抗体的方法 |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| TW202448946A (zh) | 2018-05-25 | 2024-12-16 | 美商阿列克特有限責任公司 | 抗-sirpa 抗體及其使用方法 |
| CN119868398A (zh) | 2018-06-14 | 2025-04-25 | 株式会社明治 | 用于促进免疫检查点抑制疗法的组合物 |
| KR20210044220A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| SG11202013170RA (en) | 2018-07-11 | 2021-01-28 | Kahr Medical Ltd | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| PE20211491A1 (es) | 2018-09-27 | 2021-08-11 | Celgene Corp | PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113166267A (zh) | 2018-10-19 | 2021-07-23 | 俄亥俄州国家创新基金会 | 纳米工程化治疗性隐形细胞 |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| MA56119A (fr) | 2019-06-07 | 2022-04-13 | Alx Oncology Inc | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
| BR112022008817A2 (pt) | 2019-11-27 | 2022-07-26 | Alx Oncology Inc | Terapias combinadas para tratamento de câncer |
| KR20230018475A (ko) | 2020-06-01 | 2023-02-07 | 알렉소 온콜로지 인크. | 암 치료용 저메틸화제를 포함하는 병용 요법 |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| CN116472351A (zh) | 2021-08-17 | 2023-07-21 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| EP4532548A1 (en) | 2022-06-01 | 2025-04-09 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| CN120202222A (zh) | 2022-11-16 | 2025-06-24 | 勃林格殷格翰国际有限公司 | 抗SIRPa抗体的疗效预测性生物标志物 |
| CN115896015B (zh) * | 2023-02-08 | 2023-09-29 | 上海诚益生物科技有限公司 | 一种髓系来源抑制性细胞的体外培养方法 |
| CN117054649A (zh) * | 2023-08-04 | 2023-11-14 | 广州中医药大学第一附属医院 | 一种慢性萎缩性胃炎向胃癌转化标志物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1048299A1 (en) | 1999-04-28 | 2000-11-02 | Faculteit der Geneeskunde van de Vrije Universiteit | Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| EP3424525A1 (en) * | 2007-10-12 | 2019-01-09 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
| FI3056514T4 (fi) * | 2008-01-15 | 2025-10-06 | Univ Leland Stanford Junior | Menetelmät cd47:n välittämän fagosytoosin manipuloimiseksi |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| US10907209B2 (en) | 2009-05-15 | 2021-02-02 | University Health Network | Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction |
| GB201015765D0 (en) * | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
| US8883497B2 (en) * | 2011-04-28 | 2014-11-11 | University Of Southern California | Human myeloid derived suppressor cell cancer markers |
| US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| EP3766511A1 (en) | 2012-01-17 | 2021-01-20 | The Board of Trustees of the Leland Stanford Junior University | High affinity sirp-alpha reagents |
| WO2014123580A1 (en) * | 2013-02-06 | 2014-08-14 | Inhibrx Llc | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| AU2015229448B2 (en) | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
-
2014
- 2014-10-24 EP EP14190370.8A patent/EP3012271A1/en not_active Withdrawn
-
2015
- 2015-10-21 PL PL15794641T patent/PL3209691T3/pl unknown
- 2015-10-21 US US15/518,803 patent/US20170247464A1/en not_active Abandoned
- 2015-10-21 CA CA2964203A patent/CA2964203C/en active Active
- 2015-10-21 EP EP25219878.3A patent/EP4691569A2/en active Pending
- 2015-10-21 JP JP2017520986A patent/JP6918279B2/ja active Active
- 2015-10-21 DK DK15794641.9T patent/DK3209691T3/da active
- 2015-10-21 WO PCT/IB2015/058124 patent/WO2016063233A1/en not_active Ceased
- 2015-10-21 HU HUE15794641A patent/HUE050318T2/hu unknown
- 2015-10-21 DK DK20177260.5T patent/DK3783027T3/da active
- 2015-10-21 EP EP15794641.9A patent/EP3209691B1/en not_active Revoked
- 2015-10-21 ES ES15794641T patent/ES2817074T3/es active Active
- 2015-10-21 EP EP20177260.5A patent/EP3783027B1/en active Active
-
2021
- 2021-06-21 JP JP2021102148A patent/JP7253008B2/ja active Active
-
2022
- 2022-05-20 US US17/749,856 patent/US20220281993A1/en not_active Abandoned
-
2023
- 2023-03-24 JP JP2023047480A patent/JP2023078398A/ja active Pending
-
2024
- 2024-04-25 US US18/645,607 patent/US20240294659A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538669A5 (enExample) | ||
| Chen et al. | Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response | |
| Gottstein et al. | Susceptibility versus resistance in alveolar echinococcosis (larval infection with Echinococcus multilocularis) | |
| Khammari et al. | Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones | |
| MX2019005125A (es) | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. | |
| JP2009525478A5 (enExample) | ||
| Conti et al. | Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB‐neuT Mice | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| JP2016501013A5 (enExample) | ||
| WO2007071389A1 (en) | Method for treating disseminated cancer | |
| EA201591219A1 (ru) | Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение | |
| WO2019079624A3 (en) | Msi from liquid biopsies | |
| Costa et al. | Diagnosis of human strongyloidiasis: Application in clinical practice | |
| WO2021150936A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
| WO2020081579A8 (en) | Monoclonal antibodies against human dickkopf3 and uses thereof | |
| Woller et al. | Virus infection, inflammation and prevention of cancer | |
| Cachot et al. | 545 Tumor-specific cytolytic CD4 T cells mediate protective immunity against human cancer | |
| CN116940378A (zh) | 神经内分泌癌的治疗 | |
| Jacobsen et al. | 544 Multiomic characterization of T-cell populations at the single-cell level utilizing sensitive dextramers and BD® AbSeq on the BD RhapsodyTM Single-Cell Analysis system | |
| Jackson et al. | Immu-18. Immunogenomic responder phenotype from a phase I trial of anti-LAG3 or anti-CD137 alone and in combination with anti-PD-1 in patients with recurrent GBM | |
| Jin et al. | IMMU-15. A UNIQUE SELF-STIMULATIVE PROPERTY OF CD70 CAR ADVANCES T CELL FUNCTION AND ANTI-TUMOR RESPONSE IN GLIOBLASTOMA | |
| Vaishnav et al. | Nanobytes-molecular and immuno-oncology | |
| Weiss et al. | IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS | |
| Khanniche et al. | 546 The differentiation status of systemic PD1+ CD8 T cells is associated with favorable outcome to PD1 blockade therapy in non small cell lung cancer |